Genelux (GNLX) Capital Expenditures (2022 - 2026)
Genelux (GNLX) posted quarterly Capital Expenditures of $921000.0 for Q1 2026, up 2970.0% year-over-year from $30000.0 in Q1 2025, and up 111.24% quarter-over-quarter from $436000.0 in Q4 2025.
Genelux (GNLX) Capital Expenditures (2022 - 2026) Analysis & Trends
Genelux's Capital Expenditures history runs 5 years deep, the most recent figure standing at $921000.0 for Q1 2026.
- In Q1 2026, Capital Expenditures rose 2970.0% year-over-year to $921000.0; the TTM figure through Mar 2026 stood at $2.0 million (up 422.05% YoY), while the FY2025 annual figure was $1.1 million, up 188.19% from the prior year.
- Capital Expenditures for Q1 2026 stood at $921000.0, up from $436000.0 in the prior quarter.
- The five-year high for Capital Expenditures was $921000.0 in Q1 2026, with the low at $15000.0 in Q1 2022.
- The 5-year median for Capital Expenditures is $171500.0 (2024), against an average of $245714.3.
- The sharpest annual moves came in 2024 and 2026: Capital Expenditures tumbled 90.25% in 2024, then jumped 2970.0% in 2026.
- Genelux's Capital Expenditures stood at $15000.0 in 2022, then surged by 1520.0% to $243000.0 in 2023, then plunged by 60.49% to $96000.0 in 2024, then surged by 354.17% to $436000.0 in 2025, then surged by 111.24% to $921000.0 in 2026.
- Business Quant data shows GNLX's Capital Expenditures at $921000.0 in Q1 2026, $436000.0 in Q4 2025, and $517000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 251.02 Mn |
| 10 | Genelux | 119.87 Mn | 119.87 Mn | - | 921,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 921,000.00 |
| Mar 31, 2026 | 921,000.00 |
| Dec 31, 2025 | 436,000.00 |
| Dec 31, 2025 | 436,000.00 |
| Sep 30, 2025 | 517,000.00 |
| Sep 30, 2025 | 517,000.00 |
| Jun 30, 2025 | 115,000.00 |
| Jun 30, 2025 | 115,000.00 |
| Mar 31, 2025 | 30,000.00 |
| Mar 31, 2025 | 30,000.00 |
| Dec 31, 2024 | 96,000.00 |
| Dec 31, 2024 | 96,000.00 |
| Sep 30, 2024 | 27,000.00 |
| Sep 30, 2024 | 27,000.00 |
| Jun 30, 2024 | 228,000.00 |
| Jun 30, 2024 | 228,000.00 |
| Mar 31, 2024 | 30,000.00 |
| Mar 31, 2024 | 30,000.00 |
| Dec 31, 2023 | 243,000.00 |
| Dec 31, 2023 | 243,000.00 |